Foundation Medicine – Page 4 – Healthcare Data News

Advancing digital health applications: priorities for innovation in real-world evidence generation

Ariel D Stern 1, Jan Brönneke 2, Jörg F Debatin 2, Julia Hagen 2, Henrik Matthies 2, Smit Patel 3, Ieuan Clay 4, Bjoern Eskofier 5, Annika Herr 6, Kurt Hoeller 7, Ashley Jaksa 8, Daniel B Kramer 9, Mattias Kyhlstedt 10, Katherine T Lofgren 11, Nirosha Mahendraratnam 12, Holger Muehlan 13, Simon Reif 14, Lars Riedemann 15, Jennifer C Goldsack 3 Affiliations 1Technology and Operations Management...

February 22, 2022 Competitor News Oncology Product Updates

U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for KEYTRUDA® (pembrolizumab) to Identify Patients with Microsatellite Instability-High (MSI-H) Solid Tumors

Foundation Medicine’s tissue-based comprehensive genomic profiling test is now the first and only FDA-approved companion diagnostic to aid in identifying patients with MSI-H solid tumors who may benefit from immunotherapy...

February 16, 2022February 21, 2022 Competitor News Government/Regulatory Oncology Product Updates

Foundation Medicine’s ctDNA Monitoring Assay, FoundationOne®Tracker, Granted Breakthrough Device Designation by U.S. Food and Drug Administration

February 15, 2022 06:56 AM Eastern Standard Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, today announced that the U.S. Food and Drug Administration (FDA)...

February 9, 2022February 14, 2022 Collaborations Competitor News Oncology Pharma

Foundation Medicine Announces Global Collaboration With Lilly to Develop FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for RETEVMO® and Loxo Oncology at Lilly’s Pipeline Programs

February 09, 2022 06:55 AM Eastern Standard Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. today announced a collaboration with Eli Lilly and Company (Lilly) for the development of Foundation Medicine’s tissue- and...

January 27, 2022 Academic Collaborations Competitor News COVID-19 Data Partnership RWE Study

Tag: Foundation Medicine

Advancing digital health applications: priorities for innovation in real-world evidence generation

U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for KEYTRUDA® (pembrolizumab) to Identify Patients with Microsatellite Instability-High (MSI-H) Solid Tumors

Foundation Medicine’s ctDNA Monitoring Assay, FoundationOne®Tracker, Granted Breakthrough Device Designation by U.S. Food and Drug Administration

Foundation Medicine Announces Global Collaboration With Lilly to Develop FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for RETEVMO® and Loxo Oncology at Lilly’s Pipeline Programs

The risk of COVID-19 infection in patients with atopic dermatitis: A retrospective cohort study

Guardant Health and Foundation Medicine Reach Settlement in Digital Sequencing Technology Litigation

FoundationOne®CDx Receives FDA Approval as a Companion Diagnostic for BRAF Inhibitor Therapeutics in Melanoma

Medical AI Provider Lunit Raises $61M in Funding Round Led By Major Global Healthcare Investors

Foundation Medicine Appoints Dymeka Harrison as Chief Commercial Officer

Foundation Medicine Appoints Mia Levy, MD, PhD as Chief Medical Officer